Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraints.
Winneroski, L.L., Erickson, J.A., Green, S.J., Lopez, J.E., Stout, S.L., Porter, W.J., Timm, D.E., Audia, J.E., Barberis, M., Beck, J.P., Boggs, L.N., Borders, A.R., Boyer, R.D., Brier, R.A., Hembre, E.J., Hendle, J., Garcia-Losada, P., Minguez, J.M., Mathes, B.M., May, P.C., Monk, S.A., Rankovic, Z., Shi, Y., Watson, B.M., Yang, Z., Mergott, D.J.(2020) Bioorg Med Chem 28: 115194-115194
- PubMed: 31786008 
- DOI: https://doi.org/10.1016/j.bmc.2019.115194
- Primary Citation of Related Structures:  
6UVP, 6UVV, 6UVY, 6UWP, 6UWV - PubMed Abstract: 
Inhibition of BACE1 has become an important strategy in the quest for disease modifying agents to slow the progression of Alzheimer's disease. We previously reported the fragment-based discovery of LY2811376, the first BACE1 inhibitor reported to demonstrate robust reduction of human CSF Aβ in a Phase I clinical trial ...